prior Also on XX:XX Thank our quarter and call me joining today year-end morning Titan you, Financial progress see Building Chief are update share our on accomplishments is Lemieux, XXXX calls, quarterly what Medical's welcome and of with discussed XX:XX the Kristen. to to updates today you the And we good horizon for fourth call. details we upon pleased on Officer. and Titan. financial on we Stephen
an our For getting focused had with the several assisted we single Exemption FDA. application robotic have heads access for the on past Investigational months the Enos surgical platform down Device ready
presentations, system pathway in discussed of is Novo As recent using Enos the a marketing FDA multistep a De process. the authorization
our on with understanding XXXX looking mid-XXXX, clinical to we are with have trial and clinical to and of approval. human have We effect. confident anticipation in sites. file resources application clinical reaching trials of track We productive with started in remain timeline disclosed and partnered previously after commenced XX:XX the trials IDE our out In process QX are the Benchmark and beginning
innovative, hard platform employees to on to partners mission this market. and worked have bring to differentiated Our and our proprietary deliver
us to Medtronic A hospitals receipt and patient and XXXX of process of steps are production used the loan prior quarter and goal after and instruments will These the final at surgical units capital now our proprietary the meeting our that including were summer. loaded milestone the senior months access assistant the having be delivered retire cameras multi-articulating fourth with We software to facility. through the Medtronic. QX. achieved in of the During few a in first Carolina accomplishments and of steps verification XX:XX robotic patient workstations for all partner last portion surgeons company of North drives over cards with has the proceeds Chapel past of demands Hill, completion several the of and closer validation improving goal, single manufacturing and of Titan put -- equipment operations our the ahead payment announced our Benchmark of the system surging Enos this. Our up to the outcomes testing and leveraged secured interaction over with platform as
We're to more than the building instrument company's portfolio in licensed some and XX:XX our the own are clear, entire our geographical regarding the all includes XXX notification The to portfolio with continue portfolio resolve applications. and have Head currently our deficiency. expansion We retain own NASDAQ revenue-generating intellectual price patent third have the for Manufacturing continuing to China, to States, minimum we we use respect portfolio out patents Japan, and options the capability to XX:XX and to options Operations to grow. summer. IP Europe, to Canada, continues new evaluate and our and products property coverage of evaluate third-parties. of be announce for comprehensive and We camera Korea, rights services. look manufacturing while expanded a the we This To of this United before IPs IP beginning With deficiency, available parties, our to opportunities surgery Australia. robotic bid
We taken of CEO. transition the I've role CEO also Interim announced President the where and
tier formal are a on later process and search for We have using transition firm hopeful top already recruiting started a year. this CEO a
VP Strategy American last Meeting VP Development Chris and week. Marketing Upstream Endoscopic Basra, SAGES Society and and our Gastrointestinal our Annual Seibert, Deepak the addition attended Surgeons, In of Business
Conference Both presentations and and XXXX on Annual XX:XX to earlier this innovations XXnd website. in our Company month. are Investor presented addition HC advancements, participated Oppenheimer's I software. in latest Conference Finally, In they looked surgeons and then our available on BioConnect the updating January & in advanced Investor Wainwright
remains to unchanged since Enos timeline we of system the marketing investors fall. authorization last updated Our
on progress against to we As continue our timeline, mitigate risks. we
for result the request authorization, classification the discussions a Q-Submission utilizing as marketing informative facility. We are productive with with De FDA that proceeding plans pathway of Novo using and
system We a IDE IDE the FDA the have XXXX. XX:XX during our from early I approval, timelines we disclosed the of in with Upon and will of application to FDA happy QX response Our anticipated in file completion anticipates well. is submit on study sites. the in available sorry. the quarter to authorization first the the first XX:XX on request what plan update company to plans with half and I'm clinical focused, and begin we launch remain at extremely second half of XXXX anticipate from of classification our the Commencing in expect As -- are of clinical FDA, of the study mentioned, Enos to XXXX. marketing of XX De currently properly launch the IDE XXXX. in to IDE XXXX. will system three the trials XX the we start Enos a performed four receipt to hysterectomies information IDE Commercial upon clinical Novo driven. the to that Following am the laparoscopic receiving us resourced XXXX that They team patients given total unchanged include report from human previously executing FDA
partnership capital cards workstations with well our and contract have and first summer. Benchmark, this to Our equipment patient on the manufacturer, built going track production is
IDE systems with application. results We through testing extensive our being validation and into incorporated all will verification these run
access this and single impacted our that plans outlook continue and where We we COVID and rapidly assemble Ukraine-Russia mitigations differentiated monitor changing company continue Hill, surgical we by robotic manufacturing events, highly our variance XX:XX issues, will proprietary and to be and environment instruments. in build conflict, in optimistic. out game the Although positive cameras world Chapel and proprietary long-term believe and chain not changer. place. supply shareholders for will platform Enos in-house we including facility put to currently the contingency The a remains our our We assisted are
independent Medtronic and role initial Titan's the surgical continues the trauma the be the surgery population area a as Enos extension. in system demands, patients' licensing and and program body, recently the benign the and healing, based to you estimates believe will access is assisted partnerships US surgery. and leading research to As market. annually. to include on single single concluded gynecology XX:XX Our motivated gynecology access property will a needs anticipate US development res slide, our clinical as embrace for We in medications. US XX:XX independently and and our urology, conducted non-res intellectual at company faster approximately clinical portfolio Looking solution it XXXX next XXX,XXX patient market focus robotic in on innovator aligns this like natural pain urology the scarring see market minimize reduced with this procedures grow We particularly opportunity, of validate focus fewer to performed
Moreover, to X% million Based LTV to XXX We share, system calculate of system. capture anticipate calculations of the weighted we Enos market financial year on system $X Enos a own surgeons we could are wide on based completed return per offer per insights leading range multiple attractive our and plan versatility and to broad on recently opportunities that capital the for investor meet procedures market us their annual we research per expecting our we use for Board to long-term or studies specialties. investor activities. closely work our feedback be of conferences Surgeon with participate our Stephen very to sub the with in investors We XX:XX and regarding I needs. other of Advisory in institutional obtain increased will part and as outreach unmet investors and investments. value believe risk will continue and satisfy approximately other targeting preclinical
strengthened turn results. heightened our economics. impacting Officer Lemieux, our review see with positively improving Titan's call to relationships narrative system will the hospital it to the for outcomes, have over and providing We patient ergonomic now alternative developing Chief to journalists how technology Stephen and surgeons health Stephen? financial our I we Financial XX:XX Enos a
